Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.

@article{Sjstrm2015DapagliflozinLB,
  title={Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.},
  author={Carl David Sj{\"o}str{\"o}m and Peter A Johansson and Agata Ptaszynska and J. F. Van Der List and Eva Johnsson},
  journal={Diabetes & vascular disease research},
  year={2015},
  volume={12 5},
  pages={
          352-8
        }
}
The effect of dapagliflozin on blood pressure was evaluated in non-hypertensive (<140 mm Hg) and hypertensive (⩾140 mm Hg) patients with type 2 diabetes mellitus. Data were pooled from 13 placebo-controlled studies. Patients received dapagliflozin 10 mg/day (n = 2360) or placebo (n = 2295) for up to 24 weeks. Dapagliflozin was associated with placebo-subtracted changes from baseline in systolic and diastolic blood pressures of -3.6 and -1.2 mm Hg, respectively, in hypertensive patients and -2.6… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure

Vascular health and risk management • 2016
View 6 Excerpts
Highly Influenced

Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus

Acta Diabetologica • 2016
View 6 Excerpts
Highly Influenced